Cancer involves a failure of the immune system in one of two ways: 1) the immune system is unable to recognize the tumor as foreign, and/or 2) the immune response is disabled or shut down by the tumor.
Replimune is pioneering a novel class of tumor-directed oncolytic immunotherapies (TDOI) designed to kill the tumor locally, alter the tumor microenvironment, and ignite a powerful patient-specific immune response. These transformational new therapies are being developed to be tolerable and treat difficult-to-treat cancers.
Ongoing Clinical Trials
Replimune has multiple ongoing clinical programs evaluating the safety and effectiveness of our investigational therapies in a range of solid tumor cancers, both when given as a single agent and in combination with other immunotherapies.